Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AVPR2 | P30518 | 20/20 | 0.69 |
| ▸ | AVPR1A | P37288 | 20/20 | 0.69 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.47 |
| ▸ | OXTR | P30559 | 1/20 | 0.47 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.47 |
| ▸ | AVPR1B | P47901 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL807939 | 0.93 | AVPR2 (0.70) | AVPR2AVPR1ASLC6A2OXTROPRK1 | |
| SCHEMBL716534 | 0.93 | AVPR2 (0.73) | AVPR2AVPR1ASLC6A2OXTROPRK1 | |
| SCHEMBL385140 | 0.93 | AVPR2 (0.73) | AVPR2AVPR1ASLC6A2OXTROPRK1 | |
| SCHEMBL462943 | 0.93 | AVPR2 (0.73) | AVPR2AVPR1ASLC6A2OXTROPRK1 | |
| SCHEMBL460819 | 0.93 | AVPR2 (0.73) | AVPR2AVPR1ASLC6A2OXTROPRK1 | |
| SCHEMBL715845 | 0.93 | AVPR2 (0.73) | AVPR2AVPR1ASLC6A2OXTROPRK1 | |
| SCHEMBL10129836 | 0.92 | AVPR2 (0.68) | AVPR2AVPR1ASLC6A2OXTROPRK1 | |
| SCHEMBL6915489 | 0.92 | AVPR2 (0.71) | AVPR2AVPR1A | |
| SCHEMBL1441140 | 0.90 | AVPR2 (0.70) | AVPR2AVPR1A | |
| SCHEMBL11907041 | 0.90 | AVPR2 (0.70) | AVPR2AVPR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2616448-B1 | SUBSTITUTED PHENYLACETATE AND PHENYLPROPANE AMIDES AND USE THEREOF | BAYER IP GMBH (DE) | 2016-07-20 | — | — | EP | disclosed |
| US-9034855-B2 | Substituted phenylacetate and phenylpropane amides and use thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-05-19 | — | — | US | disclosed |
| US-9034855-B2 | Substituted phenylacetate and phenylpropane amides and use thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-05-19 | — | — | US | disclosed |
| US-20130231313-A1 | SUBSTITUTED PHENYLACETATE AND PHENYLPROPANE AMIDES AND USE THEREOF | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-09-05 | — | — | US | disclosed |
| US-20130231313-A1 | SUBSTITUTED PHENYLACETATE AND PHENYLPROPANE AMIDES AND USE THEREOF | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-09-05 | — | — | US | disclosed |
| WO-2012035075-A1 | SUBSTITUTED PHENYLACETATE AND PHENYLPROPANE AMIDES AND USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130231313-A1 | SUBSTITUTED PHENYLACETATE AND PHENYLPROPANE AMIDES AND USE THEREOF | AADAC, NAT1, DNPEP | AVPR2 905/4885AVPR1A 751/4885SLC6A2 313/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.